Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · IEX Real-Time Price · USD
45.16
-1.21 (-2.61%)
At close: May 17, 2024, 4:00 PM
46.19
+1.03 (2.28%)
After-hours: May 17, 2024, 7:09 PM EDT
Legend Biotech Revenue
Legend Biotech had revenue of $342.80M in the twelve months ending March 31, 2024, with 231.84% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $93.99M with 158.67% year-over-year growth. In the year 2023, Legend Biotech had annual revenue of $285.14M with 143.70% growth.
Revenue (ttm)
$342.80M
Revenue Growth
+231.84%
P/S Ratio
24.03
Revenue / Employee
$187,732
Employees
1,826
Market Cap
8.24B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 285.14M | 168.14M | 143.70% |
| Dec 31, 2022 | 117.01M | 48.18M | 70.00% |
| Dec 31, 2021 | 68.83M | -6.17M | -8.23% |
| Dec 31, 2020 | 75.00M | 15.02M | 25.04% |
| Dec 31, 2019 | 59.98M | 10.85M | 22.08% |
| Dec 31, 2018 | 49.13M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Encompass Health | 4.96B |
| Elanco Animal Health | 4.37B |
| Bio-Rad Laboratories | 2.61B |
| Chemed | 2.29B |
| Globus Medical | 1.90B |
| Penumbra | 1.10B |
LEGN News
- 5 days ago - Legend Biotech Reports First Quarter 2024 Results and Recent Highlights - Business Wire
- 26 days ago - CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma - Business Wire
- 5 weeks ago - Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results - Business Wire
- 6 weeks ago - Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma - Business Wire
- 2 months ago - Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report - Business Wire
- 2 months ago - CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma - Business Wire
- 2 months ago - Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights - Business Wire
- 3 months ago - Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy - Business Wire